Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc. a clinical stage biopharmaceutical company focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006) an anti-CD73 monoclonal antibody which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818 a covalent inhibitor of ITK which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444) an oral small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182 an antibody designed to block inflammation and myeloid suppression; and CPI-935 an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals Inc. was incorporated in 2014 and is based in Burlingame California.